Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT04833894 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT04833894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04833894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis
Lead sponsor
argenx
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 26, 2021
Completion date
March 31, 2027
Enrollment
12 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis